Loading…
← CockpitCompetitor Analysis › GERN Geron CorporationOpen in the cockpit ↗

Geron CorporationGERNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 17
Mkt cap
$638M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$20.0M
20-day average traded
Fwd P/E
17.4×
forward earnings
ROIC−WACC
-14.9 pp
WACC 7.4%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$0.99
1D-0.9%
1W-2.9%
1M-20.1%
3M-36.1%
6M-21.4%
YTD-24.9%
1Y-12.3%
ATR %7.4%
Beta1.41
52w lowhigh50.7% off high

What Geron does

Employees: 258

Geron at a glance

Size Geron (GERN) is a United States Health Care company (Biotechnology) with a market value of $638M, the 2516th largest of 3,085 United States companies the cockpit tracks. Shares closed at $0.99 on 18 Nov 2026.

Performance Over six months the shares fell 21.4%, against -13.8% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 19 in its peer set.

Growth Revenue grew 18.6% over the last twelve months (peer median +18.1%); the operating margin is -8.2% (peer median -178.2%).

Valuation It trades at 17.4× forward earnings against a peer median of 23.2× (cheapest of 5).

Capital Return on invested capital runs 14.9 points below its cost of capital (7.4% WACC).

Short interest Short interest is 10.4% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 87GERN 79
Six months, rebased to 100: Geron against the median of its 20 peers (local-currency closes).

Geron financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$218M$184M$77.0M$237,000$596,000
Revenue growth—+139%+32,387%-60%—
Gross profit$206M$179M$75.7M-$796,000-$272,000
EBITDA-$16.7M-$50.3M-$173M-$193M-$138M
Net income-$50.1M-$83.5M-$175M-$184M-$142M
Free cash flow-$91.2M-$111M-$219M-$169M-$128M
Capital expenditure$629,000$49,000$680,000$830,000$431,000
Total debt$250M$252M$247M$85.9M$55.8M

Quarterly statements and history in the cockpit →

Geron competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%002880JANX60338768819768822199667729SRZNPRMEFDMTATTOGNFTGERN6-month return →1-month return →
Up and to the right = strong over both horizons. Geron is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×200×400×0028809966688639GNFTGERNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Geron is the large dot.

Geron competitors and peer comparison

How Geron compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Geron against its 20 peers (data as of 18 Nov 2026)
MeasureGERNPeer medianRank in peer set
1-month return-20.1%-8.4%6th lowest of 21
6-month return-21.4%-13.8%9th lowest of 19
Distance from 52-week high-50.7%-44.5%8th lowest of 21
Revenue growth (TTM)+18.6%+18.1%8th highest of 16
Operating margin-8.2%-178.2%5th highest of 17
Forward P/E17.4×23.2×cheapest of 5
ROIC minus cost of capital-14.9 pp-15.2 pp5th highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Geron GERNUnited States$638M-21%+19%-8%17.4×n/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%19.2×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%n/a-8.9%-1.3%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%n/an/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%n/a40.3%+21.5%
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%24.0×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%n/an/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%22.3×n/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%n/an/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%n/a44.8%+14.7%
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%n/an/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%n/an/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%n/an/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%n/an/an/a
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%n/an/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%431.5×39.8%+143.5%
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a

Questions

Which companies are Geron's closest peers?
The cockpit's peer set: Shenzhen Weiguang Biological Products (002880.SZ), Janux Therapeutics (JANX), Getein Biotech (603387.SS), Shouyao Holdings Beijing (688197.SS), Frontier Biotechnologies (688221.SS), Alphamab Oncology (9966.HK), Steminent Biotherapeutics (7729.TWO), Design Therapeutics (DSGN).
Is Geron expensive compared with its peers?
On forward p/e it trades at 17.4× against a peer median of 23.2×, cheapest of 5 in its peer set.
How has Geron stock performed?
Over six months to 18 Nov 2026 the shares returned -21.4% against -13.8% for the median peer; over one year -12.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.